Developing new medications to help people stop using cocaine
Advancing mGlu1 positive allosteric modulators as therapeutics to facilitate abstinence in cocaine use disorder
This study is looking at a new medication that could help people with cocaine addiction by reducing their cravings, making it easier for them to stay on the path to recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eleutheria Pharmaceuticals LLC NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10577196 on NIH RePORTER |
What this research studies
This research focuses on creating new therapeutic agents that target the metabotropic glutamate receptor 1 (mGlu1) to help reduce cravings in individuals with cocaine use disorder. The approach involves using positive allosteric modulators (PAMs) that can reverse the brain changes associated with cocaine craving. By studying how these modulators affect brain synapses, the research aims to identify effective treatments that could facilitate long-term abstinence from cocaine. Patients may benefit from a new medication that could lessen their cravings and support their recovery efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cocaine use disorder who experience cravings and are seeking treatment options.
Not a fit: Patients who do not have a cocaine use disorder or those who are not experiencing cravings may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new FDA-approved medication that significantly reduces cocaine cravings and supports recovery.
How similar studies have performed: Previous research has shown promise in targeting glutamate receptors for addiction treatment, indicating potential success for this novel approach.
Where this research is happening
Portland, United States
- Eleutheria Pharmaceuticals LLC — Portland, United States (Active)
Researchers
- Principal investigator: Wolf, Marina Elizabeth — Eleutheria Pharmaceuticals LLC
- Study coordinator: Wolf, Marina Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.